SciELO - Scientific Electronic Library Online

 
vol.36 issue4Treatment with benznidazole in association with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi: investigation into the possible development of neoplasias author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

Share


Revista da Sociedade Brasileira de Medicina Tropical

Print version ISSN 0037-8682

Rev. Soc. Bras. Med. Trop. vol.36 no.4 Uberaba July/Aug. 2003

http://dx.doi.org/10.1590/S0037-86822003000400001 

ARTIGO

 

Evaluation of the immune response to CRA and FRA recombinant antigens of Trypanosoma cruzi in C57BL/6 mice

 

Avaliação da resposta imune em camundongos C57BL/6 imunizados com os antígenos recombinantes CRA e FRA de Trypanosoma cruzi

 

 

Valéria Rêgo Alves PereiraI; Virginia Maria Barros de LorenaI; Mineo NakazawaI; Ana Paula Galvão da SilvaIII; Ulisses MontarroyosI; Rodrigo Correa-OliveiraII; Yara de Miranda GomesI

ICentro de Pesquisas Aggeu Magalhães da Fundação Oswaldo Cruz, Recife, PE, Brasil
IICentro de Pesquisas René Rachou da Fundação Oswaldo Cruz, Belo Horizonte, MG, Brasil
IIIUniversidade Federal de Pernambuco, Recife, PE, Brasil

Correspondence

 

 


ABSTRACT

Humoral and cellular immune responses were evaluated in 44 C57BL/6 mice immunized with the Trypanosoma cruzi recombinant antigens CRA and FRA. Both antigens induced cutaneous immediate-type hypersensitivity response. The levels of IgG1, IgG2a, IgG2b and IgG3 were high in CRA immunized mice. IgG3 was the predominant isotype. Although no difference in antibody levels was observed in FRA-immunized mice when compared to control mice, both antigens were able to induce lymphoproliferation in immunized mice. Significant differences were observed between incorporation of [3H]- thymidine by spleen cell stimulated in vitro with CRA or FRA and the control group. These results suggest that CRA and FRA could be involved in mechanisms of resistance to Trypanosoma cruzi infection.

Keywords: Trypanosoma cruzi. Recombinant antigens. Immunization. Isotypes. Lymphoproliferation.


RESUMO

As respostas imune humoral e celular foram avaliadas em 44 camundongos C57Bl/6 imunizados com os antígenos recombinantes CRA e FRA de Trypanosoma cruzi. Ambos antígenos induziram reação de hipersensibilidade do tipo imediato. Os níveis de IgG1, IgG2a, IgG2b e IgG3 foram elevados nos camundongos imunizados com CRA. IgG3 foi o isotipo predominante. Nenhuma diferença nos níveis de anticorpos foi observada em camundongos imunizados com FRA em relação aos animais controle. No entanto, ambos antígenos foram capazes de induzir proliferação de linfócitos em camundongos imunizados. Diferenças significativas foram observadas entre a incorporação da timidina - [3H] pelas células esplênicas estimuladas com CRA ou FRA e o grupo controle. Esses resultados sugerem que CRA e FRA poderão estar envolvidos nos mecanismos de resistência à infecção pelo Trypanosoma cruzi.

Palavras-chaves: Trypanosoma cruzi. Antígenos recombinantes. Imunização. Isotipos. Linfoproliferação.


 

 

Chagas' disease, caused by Trypanosoma cruzi, is endemic in several countries in Latin America. Despite initiatives to interrupt vector transmission and improvements in serum screening in blood banks, it is estimated that 16-18 million people are infected and at least 90 million are estimated to be at risk of infection (WHO)22. Due to the high prevalence of this disease and the absence of an effective treatment option, immunotherapy strategies aimed at the elimination of the parasite by the host have been gaining increased importance.

Previous studies have demonstrated that the immune response plays an important role in protection against infection with Trypanosoma cruzi in mice6 10 15. Murine infection has been used extensively as an experimental disease model since these animals develop detectable parasitemia during acute infection followed by chronic tissue infection. Patterns of susceptibility and resistance to T. cruzi are dependent on the parasite and mouse strains12 20.

Recombinant DNA technology has enabled the molecular cloning of several genes encoding antigenic T. cruzi proteins. Cloned segments of T. cruzi genes have been used to produce portions of antigenic proteins in bacteria, and several of these have been used as antigens in serodiagnosis7 11 or immunoprotection16 17 assays. Recombinant antigens have been used as tools for analyzing the immune response towards the parasite. These antigens are chemically defined and easy to produce, enabling the assay of various adjuvant and immunizing protocols.

The aim of this study was to evaluate the humoral and cellular immune responses in C57BL/6 mice immunized with two recombinant antigens of T. cruzi (CRA and FRA) and apply them to future assays of protection against the parasite. These antigens have been used, successfully in serological diagnosis of Chagas' disease7 11 18. CRA (cytoplasmic repetitive antigen) is detected in epimastigote and amastigote forms while FRA (flagellar repetitive antigen) is found in both epimastigote and trypomastigote forms12.

 

MATERIAL AND METHODS

Forty-four male C57Bl/6 mice (6-8 weeks old) were obtained from the Fundação Oswaldo Cruz colony (Rio de Janeiro, Brazil). The mice were used in accordance with the Ethical Committee for the Use of Experimental Animals guidelines from the Fundação Oswaldo Cruz/FIOCRUZ (Ministry of Health, Brazil).

The CRA and FRA recombinant proteins (a kind gift from Antonio Ferreira and Edimilson Silva, Laboratório de Reativos/Bio-Manguinhos/FIOCRUZ) were produced in Escherichia coli transformed with plasmid pQE 30 (Qiagen). The purity of these recombinant proteins was determined by SDS-10% polyacrylamide gel electrophoresis. Bands of 50 and 30kDa corresponding to CRA and FRA, respectively, were visualized on the gel silver stained. No band was visualized when the gel was stained with periodic acid-Schiff.

Two groups of 13 mice in each group were immunized with three doses of CRA (20µg) (Group 1 - G1) and FRA (12µg) (Group 2 - G2), respectively (equivalent CRA numbers of FRA molecules), by subcutaneous route in 20-day intervals. The first injection was emulsified in complete Freund's adjuvant and the following immunizations in incomplete Freund's adjuvant. The control group of 18 mice were injected with PBS and adjuvant compounds.

Ten days after the last immunization dose 5 mice from G1 and G2 and their control groups, G1-C and G2-C, respectively, were submitted to cutaneous testing. 25µl PBS containing 5µg of CRA or 3µg of FRA were injected in one hind footpad of G1/G1-C and G2/G2-C respectively and 25µl of PBS in the other footpad as the injection control. Footpad thickness was measured with a caliper (Mitutoyo-Japan) 2, 6, 12, 24, 48 and 72h after challenge with these antigens. The results were reported as the difference between the swelling of the footpad injected with antigen and the swelling of the footpad injected with PBS, and are expressed as the arithmetic mean thickness ± standard deviation (SD).

Fifteen days after the first and the third immunizations serum from 5 individual mice of each group were tested for IgG1, IgG2a, IgG2b, and IgG3 isotypes. After the optimum concentration was determined by checkerboard titration, micro-titer plates (Nunc-Immuno Plates, MaxiSorp, 96 wells, Nalge Nunc International Corporation) were coated with 1µg/ml of CRA or FRA (100µl/well) diluted in 0.05 M Na2CO3 buffer, pH 9.6 and incubated overnight at 4°C. The plates were blocked for 2h with PBS-Tween 20 (0.05%) (PBS-Tw) containing 5% fat free milk (Nestle), prior to incubation with 100µl of sera diluted (1:100) in PBS-Tw (overnight, 4oC). The bound antibodies were detected by incubation with peroxidase-conjugated isotype-specific rabbit anti-mouse immunoglobulin (Caltag). The immune complexes were revealed by addition of orthophenyldiamine-OPD and H2O2. The reaction was stopped with H2SO4 2.5N and the plates were read at 490nm on an automated ELISA reader (Bio-Rad 3550).

Twenty days after the last immunization the spleen cell suspensions of 3 mice from each group were pooled. The cells were cultured in 96-well plates at a density of 4x105 cells/well, in RPMI-1640 containing 10% of fetal calf serum (FCS), 2mM L-glutamine, 1Mm sodium pyruvate and antibiotics (streptomycin=100U/ml and penicillin=100g/ml) (Sigma Chemical Co., St Louis, MO). The cultures were stimulated in vitro with CRA (1.25µg/ml and 2.5µg/ml), FRA (1.25µ/ml and 5µg/ml), the mitogen Con A (2.5µg/ml) or maintained in culture medium alone for 72h at 37oC, in an atmosphere of 5% CO2. The cultures were pulsed with 0.5µCi/well of [3H] thymidine (Amershan Estou na duvida se deve ser Amersham) for 18h. At the end of the incubation period the lymphocytes were collected with the aid of a semi-automatic cell harvester and the incorporated radioactive thymidine measured by liquid scintillation. The results are expressed as average of triplicate cultures ± SD of the mean.

The Mann-Whitney U-test for nonparametric distributions was used to analyze the data. The differences were considered statistically significant when the P value was less than 0.05.

 

RESULTS

The data showed that mice immunized either with CRA or FRA developed cutaneous hypersensitivity reactions (Figure 1). CRA immunized mice showed a significant immediate-type hypersensitivity (ITH) reaction at 2h (p<0.05) which remained for 4h following antigenic challenge and which by 12h had faded drastically when compared to the control mice. FRA immunized mice also showed a significant ITH reaction at 2h (p<0.05). Swelling of the footpad was smaller than that observed in CRA immunized mice at the same time points. No significant difference between FRA immunized and control mice was observed after 6h (Figure 1). ITH induced by CRA was eight times greater than that induced by FRA (Figure 1A and B) at 2h after injection of the antigen in the footpad.

 

 

The kinetics of T. cruzi specific antibody levels for each IgG isotype are shown in Figure 2A, B, C and D. Fifteen days after the 1st (Figure 2A) and 3rd (Figure 2B) immunizations the levels of all IgG isotypes in CRA-immunized mice were significantly greater (p<0.05) than when compared to the values observed in control mice (IgG3 > IgG2a > IgG2b > IgG1). Although all immunoglobulin isotypes increased after the third immunization, it is clear from Figure 2A and B that IgG3 is the major isotype induced by immunization with CRA. This is in contrast to the controls where no difference in antibody levels was observed in FRA immunized mice (Figure 2).

Analysis of the cellular response was evaluated by in vitro stimulation of spleen cells with the recombinant antigens. The data obtained is presented in Figure 3A and B. Two different concentrations of the antigens were used, CRA1 and FRA1 (1.25µg/ml) and CRA2 (2.5µg/ml) and FRA2 (5µg/ml). We observed significant difference between incorporation of [3H] - thymidine by spleen cells stimulated with both antigens and controls. Con A induced strong proliferative response (data not shown).

 

 

DISCUSSION

In this study the humoral-antibody and cellular proliferative responses of C57BL/6 mice induced by immunization with the recombinant T. cruzi antigens CRA and FRA were evaluated. We have previously demonstrated that these antigens can be used for serological diagnosis of T. cruzi infection in man7 13. However, little is known about their potential role as immunogens or as potential antigens for vaccination. Thus, in this paper we present the data related to the initial evaluation of the immune responses of the resistant C57BL/6 mouse strain. These animals have been previously demonstrated to be resistant to infection by the CL strain of T. cruzi.

The analysis of the humoral immune response revealed that the recombinant antigen CRA but not FRA was able to induce significant levels of specific IgG antibody response to the immunizing antigen, where the main isotype was identified to be IgG3. This isotype is efficient activators of complement19. It is noteworthy that other isotypes that were evaluated were also present in high levels. Previous studies have demonstrated that partial protection could be obtained by the passive transfer of IgG2a and IgG2b isotypes from infected to naive mice, leading to both a reduced parasitemia and mortality9 20. Although we have not performed passive transfer of the different immunoglobulin isotypes induced by CRA, our data suggests its potential as a protective antigen since both IgG2a and IgG2b are induced at high levels when compared to the control. Our data showed that CRA also induced high levels of IgG1. According to Brodskin et al 4 IgG1 can have a protective effect through antibody-dependent cellular toxicity, phagocytosis and anaphylactic reactions.

The ITH reaction was very strong in mice immunized with CRA. These results are in agreement with the presence of IgG1 observed in the sera of CRA immunized mice. Immediate hypersensitivity reactions, that develop minutes to a few hours of antigen challenge can be due to anaphylactic antibodies or immune complexes (Arthus reaction)5. IgG1 and IgE are the only immunoglobulin isotypes that can elicit active and passive anaphylactic reaction in mice3 13, through binding to FceRI and FcgRIII, respectively, on mast cells7 14. Further studies are needed to evaluate the role of antibodies in ITH IgE responses. In addition, histopathological analyses must be performed to evaluate the type of cellular infiltrate present in the footpads.

In vitro stimulation of spleen cells from mice immunized with CRA and FRA induced significant cell proliferation to these antigens. The proliferative response was observed to be dependent on the concentrations of CRA and FRA. This demonstrates that the antigens also induce specific cellular immune responses since spleen cells from control mice did not show any significant uptake of [3H]- thymidine in the presence of the same antigenic stimulus. The potential role of the cellular immune response in the induction of protection is being evaluated by determining the cytokine pattern induced by these two antigens. This is important information that, together with the challenge experiments, will indicate the relationship between Type 1 and Type 2 responses and the putative protective immune response induced by CRA or FRA. It will also be interesting to evaluate whether combined immunization with both CRA and FRA offers more potential in inducing a protective immune response than when used singularly. These studies are currently in progress in our laboratory.

 

ACKNOWLEDGEMENTS

We thank Dra Sonia Andrade for the critical reading of the manuscript. We are grateful to Dr Samuel Goldenberg and Dr Marco Krieger for valuable suggestions. Virginia Maria Barros de Lorena is recipiente of a CNPq (PIBIC/FIOCRUZ) scholarship and Valéria Rêgo Alves Pereira is a CNPq doctoral fellow.

 

REFERENCES

1. Andrade V. Estudo imunopatológico de camundongos de seis diferentes linhagens isogênicas à infecção por três tipos de cepas do Trypanosoma cruzi. Revista de Patologia Tropical 13: 315-408, 1984.        [ Links ]

2. Andrade V, Barral-Neto M, Andrade SG. Patterns of resistance of inbred mice to Trypanosoma cruzi are determined by parasite strain. Brazilian Journal of Medical and Biological Research 18: 499-506, 1985.        [ Links ]

3. Becker EL. Nature and classification of immediate-type allergic reactions. Advances in Immunology 13: 267-313, 1971.        [ Links ]

4. Brodskyn CI, Silva AMM, Takehara HA, Mota I. IgG subclasses responsible for immune clearance in mice infected with Trypanosoma cruzi. Immunology and Cell Biology 67: 343-348, 1989.        [ Links ]

5. Crowle AJ. Delayed hypersensitivity in the mouse. Advances in Immunology 20: 197-265, 1975        [ Links ]

6. Gea S, Gruppi A, Cerban F, Pistoresi Palencia MC, Vottero-Cima E. Immune response in mice immunized with acidic antigenic fractions from Trypanosoma cruzi cytosol. Revista do Instituto de Medicina Tropical de São Paulo 34: 389-394, 1992.        [ Links ]

7. Gomes YM, Pereira VRA, Nakazawa M, Rosa DS, Fereira AGP, Silva ED, Krieger M, Goldenberg S. Serodiagnosis of chronic Chagas' disease by using EIE-Recombinant-Chagas-Biomanguinhos. Memórias do Instituto Oswaldo Cruz 96: 497-501, 2001.        [ Links ]

8. Hazenbos WLW, Gessner JE, Hofhuis FMA, Kuipers H, Meyer D, Heijnen IAFM, Schmidt RE, Sandor M, Capel PJA, Daeron M. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcgRIII (CD16) deficient mice. Immunity 5:181-188, 1996.        [ Links ]

9. Krettli AU, Brener Z. Protective effects of specific antibodies in Trypanosoma cruzi infection. Journal of Immunology 116: 755-760, 1976.        [ Links ]

10. Krettli AU, Brener Z. Resistance against T. cruzi associated to anti-living trypomastigotes antibodies. Journal of Immunology 128: 2009-2012, 1982.        [ Links ]

11. Krieger MA, Almeida E, Oelemann W, Lafaille JJ, Pereira JB, Krieger MA, Carvalho MR, Goldenberg S. Use of recombinant antigens for the accurate immunodiagnosis of Chagas' disease. American Journal of Tropical Medicine and Hygiene 46: 427-434, 1992.        [ Links ]

12. Lafaille JJ, Linss J, Krieger MA, Souto-Padron T, de Souza W, Goldenberg S. Structure and expression of two Trypanosoma cruzi genes encoding antigenic proteins bearing repetitive epitopes. Molecular Biochemical Parasitology 35: 127-136, 1989.        [ Links ]

13. Mota I, Wong D, Sadun. Mouse homocytotropic antibodies: specific differentiation between mouse 7S g1 and mouse reagin like antibodies. Life Science 7: 1289-1293, 1968.        [ Links ]

14. Miyajima L, Dombrowicz D, Martin TR, Ravetch JV, Kinet JP, Galli SJ. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and FcgRIII: assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG- dependent passive anaphylaxis. Journal of Clinical Investigation 99: 901-914, 1997.        [ Links ]

15. Nasser JR, Gómez LE, Sánchez D, Guerin M, Basombrío MA. Immunogenicity of the recombinant SAPA protein of Trypanosoma cruzi for mice. Journal of Parasitology 83: 76-81, 1997.        [ Links ]

16. Pereira-Chioccola VL, Costa F, Ribeirão M, Soares IS, Arena F, Schenkman S, Rodrigues MM. Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein. Parasite Immunology 21: 103-110, 1989.        [ Links ]

17. Santori FR, Paranhos-Bacalla GS, Silveira JF, Yamauchi LM, Araya J E, Yoshida N. A recombinant protein based on the Trypanosoma cruzi metacyclic trypomastigote 82-kilodalton antigen that induces an effective immune response to acute infection. Infection and Immunity 64:1093-1099, 1996.        [ Links ]

18. Silva ED, Pereira VRA, Gomes JAS, Nakazawa M, Lorena VMB, Cançado JR, Ferreira AGP, Krieger MA, Goldenberg S, Correa-Oliveira R, Gomes YM. Use of EIE-Recombinant-Chagas-Biomanguinhos kit to monitor cure of human Chagas' Disease. Journal of Clinical Laboratory Analysis 16: 132-136, 2002.        [ Links ]

19. Silveira SA, Kikuchi S, Fossati-Jimack L, Moll T, Saito T, Verbeek JS, Botto M, Walport MJ, Carroll M, Izui S. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. Journal of Experimental Medicine 195: 665-672, 2002.        [ Links ]

20. Takehara HA, Perini A, Silva MH, Mota I. Role of different antibody classes in protection against infection in the mouse. Experimental Parasitology 52: 137-146, 1981.        [ Links ]

21. Trischmann TM. Early parasite proliferation and host resistance in inbred strains of mice. Experimental Parasitology 62: 194, 1986.        [ Links ]

22. World Health Organization. Control of Tropical disease. Chagas' disease. A disease whose days are numbered, p. 1-6, 1996.        [ Links ]

 

 

Correspondence to
Dra. Yara M. Gomes
Depto de Imunologia/CPqAM/FIOCRUZ
Cidade Universitária, 50670-420 Recife, PE
Tel: 55 81 3301-2559. Fax: 55 81 3453-2449
e-mail: yara@cpqam.fiocruz.br

Recebido para publicação em 15/1/2003
Aceito em 10/6/2003
This work was financed partially by Bio-Manguinhos/FIOCRUZ end CNPq (grant no. CC 004/2000)